Mark your calendar for September and October 2024. Dr. Maria Waldhoer, JoAnn Trejo, and Anne Marie Quinn. Did you watch Episode #150 of the Dr. GPCR Matchmaking Mark Schmeizl, our Chief Matchmaker, can help you find your perfect match if you want Contact Mark today to get started. Dr. 13 - 17, 2024 | 20th Annual PEGS Boston Summit May 16 - 19, 2024 | ASPET 2024 May 27 - 29, 2024 | SLAS

Our CSO, Maria, has recently traveled to the US to attend the ACSMEDI-EFMC Medicinal Chemistry Frontiers The venue was the UIC Student Center East, and Chicago is a great choice for a city, Maria found it very Wednesday was a key day for Maria, as she got to participate in a panel discussion alongside Dr. Maria alongside the other panelists during Wednesday's panel discussion. Session 8 on Thursday was Maria’s turn to give a talk.

“The beauty of multiplexing is that you can do many things with one pot of samples.” — Tom Sakmar Enter

Learning the Lab, Learning Herself During her time at the contract research organization (CRO) in Ann I had a few friends who became addicted and, really sadly, many of whom actually passed away as a result

CNS disorders Predicting biological activity and design of 5-HT6 antagonists through assessment of ANN-QSAR

include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth

efficacious in multiple neuroinflammatory disease models Discovery of a potent melatonin-based inhibitor of quinone

Let’s dive into the Classified GPCR News from May 27th to June 2nd, 2024. and neurotransmitter release GPCRs in Oncology and Immunology Neurotoxicity and accumulation of CPPD quinone

Kotliar sums it up best: “We went from one receptor to many… and now, from many, we can go back to one

This is where many biotech founders lose visibility. They know how many months of runway remain, but not which strategic options are already gone . Burn rate creates the illusion of control 👉 Many biotech founders  believe they are in control because It tells you how fast cash is leaving the company, but it does not tell you how many meaningful choices When building quietly turns into surviving 👉 At a certain point, many biotech founders  believe they

It’s about finding purpose through loss, choosing academia when many peers walk away, and designing science Like many young scientists, she explored different paths and gained industry experience before realizing Why Catherine Chose Academia At a time when many early-career scientists debate whether to stay in academia

In This Session, You’ll Gain: ✅ The ability to calculate how many replicates you really  need for 95% How Many Replicates Do You Really Need? The second trap is habit. Instead, you’ll calculate exactly how many replicates are needed to detect the differences that matter

Many pharmacology experiments produce beautifully clean assay curves. Key realities pharmacologists face: Assays measure one slice of biology Disease physiology involves many be estimated rather than exact In practice, the precise maximal signal matters less than many assume A ligand may show identical EC₅₀ values in two assays while engaging receptors through very different Even potent inhibitors may fail simply because they never reach sufficient concentration in vivo .

Computational Biochemistry at Uppsala University and one of the strongest advocates for an approach that too many Closing the Trust Gap If collaboration is so effective, why do so many labs avoid it? Many startups chase elaborate simulations that look impressive on paper but do little to move drug discovery Structural biologists may capture snapshots of receptor conformations, but lack large-scale screening Overstating the precision of a model or the predictive power of an assay may look persuasive in the short

The receptor samples many states. traps: distributed networks of interactions that hold the receptor in an active state by satisfying many suggests that the difficulty an orthosteric small-molecule agonist program encounters at a family B GPCR may A series that shows good binding and weak activation, repeatedly, may be encountering the limit of what

Maria Majellaro, the transition from lab work to leadership wasn’t meticulously planned, it was a bold Maria Majellaro Maria’s career didn’t start with a desire to launch a company. It began in Bari, Italy, with a love for science nurtured by her father and fueled by childhood cartoons The academic group Maria worked with had developed a technology that allowed for flexible, fast synthesis

Recently, many novel discoveries have underlined the regulatory roles of neurotransmitters in the microenvironment Significantly, many ligands acting on neurotransmitter receptors have shown great potential for inhibiting

. 👉 Many founders ask why biotech startups fail  not after a collapse, but when the company starts to Strategy as a system for making fewer better decisions The turning point for many biotech startups comes This is where many teams escape the typical pattern of why biotech startups fail .

Terry Kenakin’s session examines not just how  binding works, but why  so many datasets mislead even But plotting on a logarithmic axis exposes how far the system may actually be from true saturation. After a ligand binds, the receptor may transition further—often via G protein coupling. Many programs unknowingly compare compounds measured under different kinetic biases. This orthosteric binding lesson closes out the year—marking 30 courses released  and 3 live AMAs hosted

Recently, AlphaFold2 has been developed to predict structure models of many functionally important proteins However, the predicted models and experimental structures were different in many aspects including the

When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. The scientific ambition may be impressive, yet the strategic narrative loses sharpness. When too many priorities move in parallel, several things happen at onc e: 👉 The primary value inflection When resources are spread across too many initiatives, demonstrating alignment becomes harder. 👉 Strategic That decline may not disrupt daily operations, but it quietly weakens positioning long before biotech

splicing events account for hundreds, if not thousands, of potentially divergent isoforms throughout many This might not be a big deal for many, but in this new era of making sure that historically excluded Pyramids: although it is very touristy, it is just a hop away from Mexico City and finds its way on many However, Reggaetón is a highly dynamic genre that attracts many here in Mexico, not to forget salsa music

Results show that for each of the 21 structures with bound ligands there exist many other GPCRs that These sites cluster at nine distinct locations, and each can be found in many different proteins.

Many such biosensors are based on the principle of Förster resonance energy transfer (FRET), and we have This methodology would be compatible with other mammalian species and with many biosensors.

In reality, many biotech startups drift into trouble without ever making a single decision that looks The problem is not one bad move, but the quiet accumulation of many small choices that are never evaluated It forms when many reasonable decisions are never examined as part of a system. Metrics may even look acceptable.

👥We have many surprises in reserve for you at the next Dr.

The second messenger cyclic adenosine monophosphate (cAMP) is a key mediator in many GPCR signaling pathways The GloSensor™ cAMP assay enables real-time monitoring of signaling downstream of many GPCRs. However, thermal instability of the biosensor may pose a problem for in vivo studies.

“Choosing one specific receptor is difficult… they’re unique because they can bind many different molecules

ambition expands without clear sequencing, the organization begins to operate in parallel across too many parallelism without hierarchy creates dilution. 👉 Strategic friction typically shows up in four ways: Too many

And yet, many founders walk out of their first FDA conversation with a quiet sense of confusion . 👉 The Illusion of Readiness 👉 Many biotech founders walk into a pre-IND meeting with quiet confidence